R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-Up – 6/3/20

1 month ago By Josh Neil
  • Share on

  • Facebook
  • Linkedin
Proventa International Weekly News
Pharma weekly news

A bit of a break from the big C-word this week, with news on three major mergers that have, like buses, all turned up at once: the Abbvie/Allergan merger has been cleared by the EU, with a divestiture; Thermo Fisher has acquired Qiagen for a hefty $11.5 billion; and Gilead buys oncology company Forty Seven for $4.9 billion. In other news, I lied about the break from Coronavirus news. The EU has offered €45 million towards a cure for COVID-19, and illness-hit India is limiting medical exports, fuelling a fear of shortages.

ABBVIE/ALLERGAN MERGER CLEARED BY EU, AFTER BRAZIKUMAB DIVESTITURE - EU regulators have cleared the $63 billion merger between Abbvie and Allergan, with one divestiture. This was the gastrointestinal autoimmune disease drug brazikumab, which proved sufficient to allay competition doubts. AstraZeneca has agreed to recover the rights to brazikumab. The European Commission feared would give the merged entity too much power in the Crohn’s and ulcerative colitis disease markets. The FTC and Irish High Court still need to ratify the merger. 

THERMO FISHER FINALLY SET TO ACQUIRE QIAGEN FOR $11.5 BILLION - Thermo Fisher Scientific has acquired Qiagen for $11.5 billion after months of difficulty. The deal should see complementary offerings among the companies’ clinical diagnostics and life science research support businesses. The two companies both offer a number of consumables and reagents in similar markets. These will require competition scrutiny from international regulators before the deal is finalised. The deal is set to conclude by the first half of 2021. 

GILEAD BUYS FORTY SEVEN FOR $4.9 BILLION - Gilead has proposed a $4.9 billion acquisition of oncology company Forty Seven. The purchase will add several blood cancer-targeting antibodies to its pipeline. The acquisition will complement therapies brought in from Kite Pharma, bought for $11.9 billion three years ago. 

In other news: 

R&D
EU offers €45 million towards COVID-19 research and development, alongside fast-track approval

Clinical Trials
FDA gives green light to Sanofi multiple myeloma medication Sarclisa

Manufacturing
India limits medicine exports, fuelling shortage worries 

That’s all for now. See you next week!

Joshua Neil, Editor
Proventa International

To ensure you remain up-to-date on the latest in clinical development, sign up for Proventa International’s Clinical Operations, Supply Chain & Pharmacovigilance Strategy Meeting 2020, hosted on 11 May in San Diego, USA.

More news

Weekly News Round-Up – 3/4/20

With the coronavirus showing no sign of letting up for the next few months at least, we won’t either, bringing you the most up-to-date news on efforts to combat Covid-19 from around the world. This week: Gilead begins remdesivir trials...

5 days ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-Up – 3/4/20

With the coronavirus showing no sign of letting up for the next few months at least, we won’t either, bringing you the most up-to-date news on efforts to combat Covid-19 from around the world. This week: Gilead begins remdesivir trials...

5 days ago

Weekly News Round-up – 27/3/20

It’s that time again! We’ve got all the news you wanted this week, as long as you wanted to read about nothing except COVID-19, constantly. But to cheer things up, we’ve left out the story that we’re heading towards a...

2 weeks ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 27/3/20

It’s that time again! We’ve got all the news you wanted this week, as long as you wanted to read about nothing except COVID-19, constantly. But to cheer things up, we’ve left out the story that we’re heading towards a...

2 weeks ago

How Close are We to a COVID-19 Treatment?

Despite the warnings of SARS, MERS, swine and bird flu, the coronavirus COVID-19 took the entire world by surprise. Governments, health workers and pharmaceutical executives were unprepared for the rapid spread of the pandemic across the globe. Now they are...

2 weeks ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

How Close are We to a COVID-19 Treatment?

Despite the warnings of SARS, MERS, swine and bird flu, the coronavirus COVID-19 took the entire world by surprise. Governments, health workers and pharmaceutical executives were unprepared for the rapid spread of the pandemic across the globe. Now they are...

2 weeks ago
Working With us

Interested?
Reserve your space